H

Haemonetics

Provides plasma collection tech and services

Production Executive

Full-TimeUpdated on 10/14/2026
No salary listed
Mid
Bachelor's
Batu Kawan, Simpang Ampat, Penang, Malaysia
In Person
Manufacturing & Production OperationsProduct Assembly

About the job

Requirements
  • A Bachelor's degree in Engineering, Manufacturing, or another relevant discipline is required.
  • Experience leading or supervising production teams, including Group Leaders, Supervisors, or production operators, is required.
  • A minimum of 3–5 years of manufacturing experience is required, including hands-on experience in box-build manufacturing or system-level assembly.
  • Strong understanding of production planning, capacity management, manpower utilization, work-in-process management, and production performance is required.
Responsibilities
  • Lead and manage the production team, including Group Leaders and team members, to achieve daily, weekly, and monthly production targets.
  • Take overall responsibility for assigned box-build products, ensuring production output, quality, delivery, and operational performance meet business and customer requirements.
  • Monitor production performance, work-in-process, manpower utilization, material availability, and other key operational indicators, and take appropriate actions to address gaps or issues.
  • Provide leadership, coaching, and guidance to Group Leaders and team members to ensure effective team performance and development.
  • Ensure employees are adequately trained, qualified, and competent to perform their assigned tasks in accordance with applicable procedures and work instructions.
  • Work closely with cross-functional teams, including Quality, Engineering, Supply Chain, Planning, and other relevant functions, to resolve production, material, quality, and process issues.
  • Drive continuous improvement initiatives to improve productivity, efficiency, quality, yield, cost, and overall manufacturing performance.
  • Ensure production activities comply with approved procedures, work instructions, and applicable quality and regulatory requirements.
  • Prepare, review, and maintain production reports, including production output, work-in-process status, material status, and other required operational reports.
  • Ensure the production area is maintained in a clean, organized, and safe condition in accordance with 5S and company requirements.
  • Promote and maintain a strong safety culture by identifying and reporting unsafe acts and conditions and ensuring appropriate corrective actions are taken.
  • Ensure compliance with the applicable Quality Management System, Environmental Management System, and regulatory requirements, including ISO 13485, ISO 14001, FDA requirements, and other applicable regulations.
  • Support the development, implementation, and continuous improvement of manufacturing processes and systems.
Desired Qualifications
  • Experience in medical device or other highly regulated manufacturing environments is highly preferred.

About the company

Haemonetics develops and sells medical technology solutions focused on improving plasma collection and critical-care operations in hospitals and plasma centers. Its products include devices and services that raise plasma yield, increase staff productivity, and enhance the donor experience, enabling healthcare providers to collect plasma more efficiently while maintaining patient care quality. The company generates revenue from one-time equipment sales and recurring service contracts and consumables used with its devices. It differentiates itself by targeting operational efficiency and patient outcomes in high-stakes settings, combining hardware, software, and services to streamline plasma collection and related processes. Haemonetics’ goal is to advance patient care by delivering reliable medical technologies that improve clinical performance and economic outcomes, while maintaining a strong focus on corporate responsibility.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1971

Get referred to Haemonetics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2027 guidance calls for 4%-7% revenue growth and 50-100 basis-point margin expansion.
  • Q4 fiscal 2026 revenue rose 4.8%, with organic ex-CSL growth at 8.6%.
  • Martin Madaus joined the board July 24, 2026, adding diagnostics and turnaround experience.

What critics are saying

  • Blood Center guidance still calls for a mid-single-digit decline in fiscal 2027.
  • Haemonetics sued Terumo BCT and Fresenius Kabi in 2026 over plasma patents.
  • A plasma share loss to Terumo BCT would gut Haemonetics core franchise.

What makes Haemonetics unique

  • Persona PLUS and NexSys PCS target donor-specific plasma yields, reinforcing switching costs.
  • VASCADE MVP XL and PerQseal Elite extend Haemonetics across vascular closure.
  • Vivasure acquisition adds proprietary closure assets and broadens hospital cross-sell.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Parental Leave
  • Disability Insurance
  • Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

8%

2 year growth

8%
PR Newswire
Oct 19th, 2026
Haemonetics wins FDA approval for PerQseal Elite large-bore vascular closure system

Haemonetics has won US Food and Drug Administration (FDA) approval for its PerQseal Elite vascular closure system, used in large-bore arterial procedures. The approval expands the company's range of large-bore closure devices for structural heart and endovascular procedures. Haemonetics acquired Vivasure Medical Limited, the device's developer, in January 2026. The sutureless system uses a fully bioabsorbable patch to seal arteriotomies up to 26F from inside the vessel. In the ELITE arterial study, it showed 0% major complications and a mean time to hemostasis under one minute. The device received CE Mark approval in Europe in 2025. Haemonetics will present clinical data at the Transcatheter Cardiovascular Therapeutics Conference at the end of October.

Yahoo Finance
Oct 16th, 2026
Haemonetics shares surge 149.3% in a year on plasma and MedSurg growth

Haemonetics shares have risen 149.3% over the past year, while the industry fell 26.8%. The S&P 500 gained 18% over the same period. Demand for the company's plasma products is driving the rally. In the first quarter of fiscal 2027, plasma revenue rose 7.2% to $155.5 million, and MedSurg revenue rose 6.0% to $148.1 million. Haemonetics raised its fiscal 2027 reported revenue growth guidance to 5-8% from 4-7%. Organic growth is now expected at 4-7%, up from 3-6%. Debt remains a concern. Long-term debt stood at $1.17 billion, and net leverage was 2.69x EBITDA. Slower product adoption, especially by the American Red Cross, could also hurt revenue.

MoneyCheck
Oct 8th, 2026
Haemonetics (HAE) stock jumps 16% as CSL Plasma commits to full U.S. Equipment deployment.

Haemonetics (HAE) stock jumps 16% as CSL Plasma commits to full U.S. Equipment deployment. Key highlights. Table of Contents * Shares of Haemonetics jumped nearly 16% following CSL Plasma's commitment to deploy NexSys devices nationwide. * The plasma collection giant aims to finish equipment installations at over 300 U.S. facilities by the end of 2027. * BTIG analysts lifted their price target to $130, while Citi previously upgraded the stock to Buy. * Recent quarterly results showed $339.38 million in revenue and diluted earnings of $0.72 per share. * Market participants anticipate November 5 earnings release for updates on CSL partnership revenue projections. Shares of Haemonetics (HAE) climbed 15.96% on Thursday, October 8, 2026, reaching approximately $118 during morning hours from the prior close of $101.71. The rally followed CSL Plasma's disclosure of plans to deploy the medical device company's plasma collection technology throughout its entire U.S. footprint. CSL Plasma commits to comprehensive U.S. Deployment. CSL Plasma informed Haemonetics of its intention to install NexSys PCS devices equipped with Persona PLUS technology across every operational U.S. plasma donation center. The company established December 2027 as the completion target for this transition, affecting a network spanning more than 300 locations. This commitment builds upon an August supply agreement granting CSL flexibility to purchase Haemonetics equipment without binding minimum order quantities. The arrangement permits CSL to source from other suppliers, and specific implementation schedules await final confirmation between the partners. Earlier in the week, European healthcare stocks gained, supported in part by positive clinical trial developments. Wall street elevates Haemonetics (HAE) price projections. BTIG analysts increased their Haemonetics price objective from $110 to $130 on Thursday, maintaining their Buy recommendation. The previous month saw Citi shift its stance from Neutral to Buy, simultaneously raising its target from $92 to $123. These revisions arrived several weeks apart. Citi's analysis suggested that every 10% recovery in CSL-related business could contribute an additional $0.13 to annual earnings per share. Independent analyst estimates have placed potential annual sales from a complete CSL transition between $183 million and $223 million, though Haemonetics has issued no official guidance on these projections. Latest financial performance and Vivasure progress. The company's June quarter delivered $339.38 million in total revenue alongside $0.72 in diluted earnings per share. Top-line growth measured 5.6% year-over-year. Free cash flow generation totaled approximately $39.1 million for the period. Meanwhile, U.S. stock indexes set records during the same week, though increasing bond yields created headwinds for select healthcare equities. Haemonetics advanced its collaboration with Vivasure Medical through a $6.1 million milestone payment to Orchestra BioMed, bringing cumulative consideration to $11 million. The partnership structure allows for an additional $10 million in contingent payments tied to specific Vivasure revenue achievements. Market valuation and upcoming earnings release. The medical device manufacturer holds roughly $1.17 billion in long-term debt and traded near 50 times trailing earnings during Thursday's surge. This valuation multiple drew increased scrutiny following the day's price advance. A recent retail investor survey revealed unusually elevated equity allocations across the broader market. Haemonetics has maintained its fiscal 2027 outlook without revision, citing uncertainty around deployment timelines and order patterns. Management scheduled its second-quarter earnings announcement for November 5, when executives plan to provide clarity on anticipated revenue contributions from the expanded CSL relationship. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Yahoo Finance
Aug 21st, 2026
Haemonetics beats Q2 revenue estimates by 2.8%, stock surges 29.5%

Haemonetics reported Q2 revenues of $339.4 million, up 5.6% year-on-year and exceeding analyst expectations by 2.8%. The medical devices company, which specialises in blood collection and processing equipment, delivered a strong quarter with beats on both organic revenue and earnings per share estimates. The company's shares have risen 29.5% since the earnings announcement and currently trade at $108.25. Across the medical devices and supplies specialty sector, the seven tracked companies reported robust Q2 results. As a group, revenues beat analyst consensus estimates by 2.1%, with share prices averaging gains of 5.6% following earnings releases. The medical devices industry benefits from recurring revenue streams but faces ongoing pricing pressures from healthcare systems and insurers focused on cost efficiency.